Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - cabergoline -

United States - English - NLM (National Library of Medicine)

greenstone llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings).

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings) - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (see warnings).

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings ).

Canada - English - Health Canada

apotex inc - cabergoline - tablet - 0.5mg - cabergoline 0.5mg - ergot-derivative dopamine receptor agonists

United States - English - NLM (National Library of Medicine)

apotex corp. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including  echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. (see warnings ) - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (see warnings )

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. (see warnings ) - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (see warnings )